Exact Sciences Co. (NASDAQ:EXAS) Shares Bought by Raymond James & Associates

Raymond James & Associates grew its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 5.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 62,925 shares of the medical research company’s stock after purchasing an additional 3,430 shares during the quarter. Raymond James & Associates’ holdings in Exact Sciences were worth $4,655,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of EXAS. Norges Bank acquired a new stake in Exact Sciences in the fourth quarter worth about $47,037,000. Capital World Investors lifted its holdings in Exact Sciences by 17.2% in the first quarter. Capital World Investors now owns 5,487,009 shares of the medical research company’s stock worth $383,652,000 after purchasing an additional 804,159 shares during the period. Vanguard Group Inc. lifted its holdings in Exact Sciences by 4.4% in the third quarter. Vanguard Group Inc. now owns 16,676,611 shares of the medical research company’s stock worth $541,823,000 after purchasing an additional 698,740 shares during the period. Artisan Partners Limited Partnership lifted its holdings in Exact Sciences by 11.8% in the third quarter. Artisan Partners Limited Partnership now owns 3,961,514 shares of the medical research company’s stock worth $270,254,000 after purchasing an additional 418,770 shares during the period. Finally, Qube Research & Technologies Ltd lifted its holdings in Exact Sciences by 328.3% in the third quarter. Qube Research & Technologies Ltd now owns 540,191 shares of the medical research company’s stock worth $36,852,000 after purchasing an additional 414,059 shares during the period. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Guggenheim began coverage on shares of Exact Sciences in a report on Thursday, December 14th. They issued a “buy” rating and a $90.00 price objective for the company. TheStreet cut shares of Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. Benchmark upgraded shares of Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 price target on the stock in a research report on Tuesday, January 2nd. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Finally, Citigroup reiterated a “buy” rating and issued a $100.00 price target on shares of Exact Sciences in a research report on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $97.44.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, EVP Sarah Condella sold 2,000 shares of Exact Sciences stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $70.00, for a total transaction of $140,000.00. Following the transaction, the executive vice president now owns 73,787 shares of the company’s stock, valued at approximately $5,165,090. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Kevin T. Conroy sold 14,791 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $908,611.13. Following the completion of the sale, the chief executive officer now owns 1,224,357 shares of the company’s stock, valued at approximately $75,212,250.51. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Sarah Condella sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $70.00, for a total value of $140,000.00. Following the completion of the sale, the executive vice president now directly owns 73,787 shares of the company’s stock, valued at approximately $5,165,090. The disclosure for this sale can be found here. Insiders have sold a total of 69,113 shares of company stock valued at $4,165,273 in the last 90 days. 1.30% of the stock is currently owned by corporate insiders.

Exact Sciences Trading Down 0.9 %

NASDAQ:EXAS opened at $72.95 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.32 and a quick ratio of 2.07. Exact Sciences Co. has a fifty-two week low of $56.05 and a fifty-two week high of $100.77. The stock’s 50-day moving average is $63.13 and its two-hundred day moving average is $65.17. The stock has a market cap of $13.24 billion, a PE ratio of -63.99 and a beta of 1.25.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.26. Exact Sciences had a negative return on equity of 6.60% and a negative net margin of 8.17%. The company had revenue of $646.89 million for the quarter, compared to analysts’ expectations of $638.83 million. During the same quarter in the previous year, the business posted ($0.72) EPS. The business’s revenue for the quarter was up 17.0% on a year-over-year basis. As a group, equities research analysts forecast that Exact Sciences Co. will post -0.86 earnings per share for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.